Role of omega-3 fatty acids in brain development and function: Potential implications for the pathogenesis and prevention of psychopathology

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 75, Issue 4-5, 2006, Pages 329-349

  McNamara, Robert K ^a   Carlson, Susan E ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; FENFLURAMINE; HALOPERIDOL; OMEGA 3 FATTY ACID; SCOPOLAMINE; SEROTONIN;

AGGRESSION; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN MATURATION; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC TRANSMISSION; GRAY MATTER; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; VISUAL ACUITY;

ANIMALS; BEHAVIOR; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; COGNITION; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; MENTAL DISORDERS; PREGNANCY; PRENATAL NUTRITION PHYSIOLOGY; PRENATAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA; PRIMATES; RODENTIA; SYNAPTIC TRANSMISSION;

ANIMALIA; PRIMATES;

EID: 33748958268     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.07.010     Document Type: Article

References (297)

1. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)?. Int. J. Vitam. Nutr. Res. 68 (1998) 159-173
2. Pawlosky R.J., Hibbeln J.R., Novotny J.A., and Salem N. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J. Lipid Res. 42 (2001) 1257-1265
3. Burdge G.C., and Calder P.C. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev. 45 (2005) 581-597
4. Mayes C., Burdge G.C., Bingham A., Murphy J.L., Tubman R., and Wootton S.A. Variation in [U-13C] alpha linolenic acid absorption, beta-oxidation and conversion to docosahexaenoic acid in the preterm infant fed a DHA-enriched formula. Pediatr. Res. 59 (2006) 272-275
5. Makrides M., Neumann M.A., Byard R.W., Simmer K., and Gibson R.A. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am. J. Clin. Nutr. 60 (1994) 189-194
6. Farquharson J., Cockburn F., Patrick W.A., Jamieson E.C., and Logan R.W. Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet 340 (1992) 810-813
7. Farquharson J., Jamieson E.C., Abbasi K.A., Patrick W.J., Logan R.W., and Cockburn F. Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex. Arch. Dis. Child 72 (1995) 198-203
8. Su H.M., Bernardo L., Mirmiran M., Ma X.H., Corso T.N., Nathanielsz P.W., and Brenna J.T. Bioequivalence of dietary alpha-linolenic and docosahexaenoic acids as sources of docosahexaenoate accretion in brain and associated organs of neonatal baboons. Pediatr. Res. 45 (1999) 87-93
9. Bowen R.A., and Clandinin M.T. Maternal dietary 22:6n-3 is more effective than 18:3n-3 in increasing the 22:6n-3 content in phospholipids of glial cells from neonatal rat brain. Br. J. Nutr. 93 (2005) 601-611
10. DeMar J.C., Ma K., Chang L., Bell J.M., and Rapoport S.I. alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J. Neurochem. 94 (2005) 1063-1076
11. Neuringer M., Connor W.E., Lin D.S., Barstad L., and Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. USA 83 (1986) 4021-4025
12. Moriguchi T., Loewke J., Garrison M., Catalan J.N., and Salem N. Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J. Lipid Res. 42 (2001) 419-427
13. Carrie I., Clement M., de Javel D., Frances H., and Bourre J.M. Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. J. Lipid Res. 41 (2000) 465-472
14. Byard R.W., Makrides M., Need M., Neumann M.A., and Gibson R.A. Sudden infant death syndrome: effect of breast and formula feeding on frontal cortex and brainstem lipid composition. J. Paediatr. Child Health 31 (1995) 14-16
15. Favreliere S., Barrier L., Durand G., Chalon S., and Tallineau C. Chronic dietary n-3 polyunsaturated fatty acids deficiency affects the fatty acid composition of plasmenylethanolamine and phosphatidylethanolamine differently in rat frontal cortex, striatum, and cerebellum. Lipids 33 (1998) 401-407
16. Soderberg M., Edlund C., Kristensson K., and Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26 (1991) 421-425
17. Xiao Y., Huang Y., and Chen Z.Y. Distribution, depletion and recovery of docosahexaenoic acid are region-specific in rat brain. Br. J. Nutr. 94 (2005) 544-550
18. Diau G.-Y., Hsieh A., Sarkadi-Nagy E.A., Wijendran V., Nathanielsz P.W., and Brenna J.T. The influence of long chain polyunsaturated supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med. 3 (2005). 〈http://www.biomedcentral.com/1741-7015/3/11〉
19. Bourre J.M., Bonneil M., Chaudiere J., Clement M., Dumont O., Durand G., Lafont H., Nalbone G., Pascal G., and Piciotti M. Structural and functional importance of dietary polyunsaturated fatty acids in the nervous system. Adv. Exp. Med. Biol. 318 (1992) 211-229
20. Breckenridge W.C., Morgan I.G., Zanetta J.P., and Vincendon G. Adult rat brain synaptic vesicles. II. Lipid composition. Biochim. Biophys. Acta 320 (1973) 681-686
21. Grandgirard A., Bourre J.M., Julliard F., Homayoun P., Dumont O., Piciotti M., and Sebedio J.L. Incorporation of trans long-chain n-3 polyunsaturated fatty acids in rat brain structures and retina. Lipids 29 (1994) 251-258
22. Jones C.R., Arai T., and Rapoport S.I. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem. Res. 22 (1997) 663-670
23. Suzuki H., Manabe S., Wada O., and Crawford M.A. Rapid incorporation of docosahexaenoic acid from dietary sources into brain microsomal, synaptosomal and mitochondrial membranes in adult mice. Int. J. Vitam. Nutr. Res. 67 (1997) 272-278
24. Yeh Y.Y., Gehman M.F., and Yeh S.M. Maternal dietary fish oil enriches docosahexaenoate levels in brain subcellular fractions of offspring. J. Neurosci. Res. 35 (1993) 218-226
25. Lee C.H., and Hajra A.K. Molecular species of diacylglycerols and phosphoglycerides and the postmortem changes in the molecular species of diacylglycerols in rat brains. J. Neurochem. 56 (1991) 370-379
26. Farooqui A.A., and Horrocks L.A. Brain phospholipases A2: a perspective on the history. Prostaglandins Leukot. Essent. Fatty Acids 71 (2004) 161-169
27. R.K. McNamara, M. Ostrander, W. Abplanalp, N.M. Richtand, S. Benoit, D. Clegg, Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostoglandins Leukot. Essent. Fatty Acids (2006), in press, doi:10.1016/j.plefa.2006.07.009.
28. Hong S., Gronert K., Devchand P.R., Moussignac R.L., and Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278 (2003) 14677-14687
29. Yavin E., Brand A., and Green P. Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr. Neurosci. 5 (2002) 149-157
30. DeMar J.C., Ma K., Bell J.M., and Rapoport S.I. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 91 (2004) 1125-1137
31. Rapoport S.I., Chang M.C., and Spector A.A. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J. Lipid Res. 42 (2001) 678-685
32. Green P., Glozman S., Kamensky B., and Yavin E. Developmental changes in rat brain membrane lipids and fatty acids. The preferential prenatal accumulation of docosahexaenoic acid. J. Lipid. Res. 40 (1999) 960-966
33. Green P., and Yavin E. Fatty acid composition of late embryonic and early postnatal rat brain. Lipids 31 (1996) 859-865
34. Schiefermeier M., and Yavin E. n-3 Deficient and docosahexaenoic acid-enriched diets during critical periods of the developing prenatal rat brain. J. Lipid Res. 43 (2002) 124-131
35. Jumpsen J.A., Lien E.L., Goh Y.K., and Clandinin M.T. During neuronal and glial cell development diet n-6 to n-3 fatty acid ratio alters the fatty acid composition of phosphatidylinositol and phosphatidylserine. Biochim. Biophys. Acta 1347 (1997) 40-50
36. Martinez M., and Mougan I. Fatty acid composition of human brain phospholipids during normal development. J. Neurochem. 71 (1998) 2528-2533
37. Ikemoto A., Nitta A., Furukawa S., Ohishi M., Nakamura A., Fujii Y., and Okuyama H. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci. Lett. 285 (2000) 99-102
38. Ikemoto A., Kobayashi T., Watanabe S., and Okuyama H. Membrane fatty acid modifications of PC12 cells by arachidonate or docosahexaenoate affect neurite outgrowth but not norepinephrine release. Neurochem. Res. 22 (1997) 671-678
39. Calderon F., and Kim H.Y. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J. Neurochem. 90 (2004) 979-988
40. Auestad N., and Innis S.M. Dietary n-3 fatty acid restriction during gestation in rats: neuronal cell body and growth-cone fatty acids. Am. J. Clin. Nutr. 71 (2000) 312S-314S
41. Innis S.M., and de La Presa Owens S. Dietary fatty acid composition in pregnancy alters neurite membrane fatty acids and dopamine in newborn rat brain. J. Nutr. 131 (2001) 118-122
42. Martin R.E. Docosahexaenoic acid decreases phospholipase A2 activity in the neurites/nerve growth cones of PC12 cells. J. Neurosci. Res. 54 (1998) 805-813
43. Martin R.E., and Bazan N.G. Changing fatty acid content of growth cone lipids prior to synaptogenesis. J. Neurochem. 59 (1992) 318-325
44. Bourre J.M., Dumont O.S., Piciotti M.J., Pascal G.A., and Durand G.A. Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content, in contrast to liver, heart and testes. Biochim. Biophys. Acta 1124 (1992) 119-122
45. Levant B., Radel J.D., and Carlson S.E. Reduced Brain DHA Content after a single reproductive cycle in female rats fed a diet deficient in n-3 polyunsaturated fatty acids. Biol. Psychiatry (2006) [Epub ahead of print]
46. B. Levant, M.K. Ozias, S.E. Carlson, Diet (n-3) polyunsaturated fatty acid content and parity interact to alter maternal rat brain phospholipid fatty acid composition. J. Nutr. 136 (2006) 2236-2242.
47. Ahmad A., Moriguchi T., and Salem N. Decrease in neuron size in docosahexaenoic acid-deficient brain. Pediatr. Neurol. 26 (2002) 210-218
48. Ahmad A., Murthy M., Greiner R.S., Moriguchi T., and Salem N. A decrease in cell size accompanies a loss of docosahexaenoate in the rat hippocampus. Nutr. Neurosci. 5 (2002) 103-113
49. Salem N., Moriguchi T., Greiner R.S., McBride K., Ahmad A., Catalan J.N., and Slotnick B. Alterations in brain function after loss of docosahexaenoate due to dietary restriction of n-3 fatty acids. J. Mol. Neurosci. 16 (2001) 299-307
50. Ahmad A., Momenan R., van Gelderen P., Moriguchi T., Greiner R.S., and Salem N. Gray and white matter brain volume in aged rats raised on n-3 fatty acid deficient diets. Nutr. Neurosci. 7 (2004) 13-20
51. Struys-Ponsar C., Florence A., Gauthier A., Crichton R.R., and van den Bosch de Aguilar P. Ultrastructural changes in brain parenchyma during normal aging and in animal models of aging. J. Neural Transm. Suppl. 44 (1994) 111-132
52. Sugiyama I., Tanaka K., Akita M., Yoshida K., Kawase T., and Asou H. Ultrastructural analysis of the paranodal junction of myelinated fibers in 31-month-old-rats. J. Neurosci. Res. 70 (2002) 309-317
53. Yoshida S., Yasuda A., Kawazato H., Sakai K., Shimada T., Takeshita M., Yuasa S., Kobayashi T., Watanabe S., and Okuyama H. Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of alpha-linolenate deficiency and a learning task. J. Neurochem. 68 (1997) 1261-1268
54. Zimmer L., Delpal S., Guilloteau D., Aioun J., Durand G., and Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci. Lett. 284 (2000) 25-28
55. Hamilton L., Greiner R., Salem N., and Kim H.Y. n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids 35 (2000) 863-869
56. Murthy M., Hamilton J., Greiner R.S., Moriguchi T., Salem N., and Kim H.Y. Differential effects of n-3 fatty acid deficiency on phospholipid molecular species composition in the rat hippocampus. J. Lipid Res. 43 (2002) 611-617
57. Chalon S., Delion-Vancassel S., Belzung C., Guilloteau D., Leguisquet A.M., Besnard J.C., and Durand G. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J. Nutr. 128 (1998) 2512-2519
58. McLaughlin S., and Aderem A. The myristoyl-electrostatic switch: a modulator of reversible protein-membrane interactions. Trends Biochem. Sci. 20 (1995) 272-276
59. Glaser M., Wanaski S., Buser C.A., Boguslavsky V., Rashidzada W., Morris A., Rebecchi M., Scarlata S.F., Runnels L.W., Prestwich G.D., Chen J., Aderem A., Ahn J., and McLaughlin S. Myristoylated alanine-rich C kinase substrate (MARCKS) produces reversible inhibition of phospholipase C by sequestering phosphatidylinositol 4,5-bisphosphate in lateral domains. J. Biol. Chem. 271 (1996) 26187-26193
60. Rauch M.E., Ferguson C.G., Prestwich G.D., and Cafiso D.S. Myristoylated alanine-rich C kinase substrate (MARCKS) sequesters spin-labeled phosphatidylinositol 4,5-bisphosphate in lipid bilayers. J. Biol. Chem. 277 (2002) 14068-14076
61. Wang J., Gambhir A., Hangyas-Mihalyne G., Murray D., Golebiewska U., and McLaughlin S. Lateral sequestration of phosphatidylinositol 4,5-bisphosphate by the basic effector domain of myristoylated alanine-rich C kinase substrate is due to nonspecific electrostatic interactions. J. Biol. Chem. 277 (2002) 34401-34412
62. Zhang W., Crocker E., McLaughlin S., and Smith S.O. Binding of peptides with basic and aromatic residues to bilayer membranes: phenylalanine in the myristoylated alanine-rich C kinase substrate effector domain penetrates into the hydrophobic core of the bilayer. J. Biol. Chem. 278 (2003) 21459-21466
63. Bolsover S.R. Calcium signalling in growth cone migration. Cell Calcium 37 (2005) 395-402
64. McNamara R.K., and Lenox R.H. The myristoylated alanine-rich C kinase substrate: a lithium-regulated protein linking cellular signaling and cytoskeletal plasticity. Clin. Neurosci. Res. 4 (2004) 155-169
65. Kodas E., Galineau L., Bodard S., Vancassel S., Guilloteau D., Besnard J.C., and Chalon S. Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J. Neurochem. 89 (2004) 695-702
66. Aid S., Vancassel S., Poumes-Ballihaut C., Chalon S., Guesnet P., and Lavialle M. Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J. Lipid Res. 44 (2003) 1545-1551
67. Zimmer L., Delion-Vancassel S., Durand G., Guilloteau D., Bodard S., Besnard J.C., and Chalon S. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J. Lipid Res. 41 (2000) 32-40
68. Calabrese B., and Halpain S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 48 (2005) 77-90
69. Matus A. Actin-based plasticity in dendritic spines. Science 290 (2000) 754-758
70. Zhou F.Q., and Cohan C.S. How actin filaments and microtubules steer growth cones to their targets. J. Neurobiol. 58 (2004) 84-91
71. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 101 (2001) 2353-2364
72. Hundle B., McMahon T., Dadgar J., and Messing R.O. Overexpression of epsilon-protein kinase C enhances nerve growth factor-induced phosphorylation of mitogen-activated protein kinases and neurite outgrowth. J. Biol. Chem. 270 (1995) 30134-30140
73. Minami H., Owada Y., Suzuki R., Handa Y., and Kondo H. Localization of mRNAs for novel, atypical as well as conventional protein kinase C (PKC) isoforms in the brain of developing and mature rats. J. Mol. Neurosci. 15 (2000) 121-135
74. Vaughan P.F., Walker J.H., and Peers C. The regulation of neurotransmitter secretion by protein kinase C. Mol. Neurobiol. 18 (1998) 125-155
75. de la Presa Owens S., and Innis S.M. Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and α-linolenic acid deficient diet in formula-fed piglets. J. Nutr. 129 (1999) 2088-2093
76. Delion S., Chalon S., Guilloteau D., Besnard J.C., and Durand G. alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 66 (1996) 1582-1591
77. Kodas E., Vancassel S., Lejeune B., Guilloteau D., and Chalon S. Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J. Lipid Res. 43 (2002) 1209-1219
78. Zimmer L., Hembert S., Durand G., Breton P., Guilloteau D., Besnard J.C., and Chalon S. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci. Lett. 240 (1998) 177-181
79. Zimmer L., Vancassel S., Cantagrel S., Breton P., Delamanche S., Guilloteau D., Durand G., and Chalon S. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am. J. Clin. Nutr. 75 (2002) 662-667
80. Bhattacharyya S., Puri S., Miledi R., and Panicker M.M. Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms. Proc. Natl. Acad. Sci. USA 99 (2002) 14470-14475
81. Namkung Y., and Sibley D.R. Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J. Biol. Chem. 279 (2004) 49533-49541
82. Apparsundaram S., Schroeter S., Giovanetti E., and Blakely R.D. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287 (1998) 744-751
83. Loder M.K., and Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278 (2003) 22168-22174
84. Ramamoorthy S., Giovanetti E., Qian Y., and Blakely R.D. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J. Biol. Chem. 273 (1998) 2458-2466
85. 2A receptor binding in the adult rat prefrontal cortex. Biol. Psychiatry 59 (2006) S146
86. Kodas E., Page G., Zimmer L., Vancassel S., Guilloteau D., Durand G., and Chalon S. Neither the density nor function of striatal dopamine transporters were influenced by chronic n-3 polyunsaturated fatty acid deficiency in rodents. Neurosci. Lett. 321 (2002) 95-99
87. I. Fedorova, N. Salem, Omega-3 fatty acids and rodent behavior, Prostaglandins Leukot. Essent. Fatty Acids, in press, doi:10.1016/j.plefa.2006.07.006.
88. Moriguchi T., Greiner R.S., and Salem N. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J. Neurochem. 75 (2000) 2563-2573
89. Moriguchi T., and Salem N. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J. Neurochem. 87 (2003) 297-309
90. Wainwright P.E., Xing H.-C., Girard T., Parker L., and Ward G.R. Effects of dietary n-3 deficiency on Morris water-maze performance and amphetamine-induced conditioned place preference. Nut. Neurosci. 1 (1998) 281-293
91. Greiner R.S., Moriguchi T., Slotnick B.M., Hutton A., and Salem N. Olfactory discrimination deficits in n-3 fatty acid-deficient rats. Physiol. Behav. 72 (2001) 379-385
92. Carrie I., Clement M., de Javel D., Frances H., and Bourre J.M. Phospholipid supplementation reverses behavioral and biochemical alterations induced by n-3 polyunsaturated fatty acid deficiency in mice. J. Lipid Res. 41 (2000) 473-480
93. DeMar J.C., Ma K., Bell J.M., Igarashi M., Greenstein D., and Rapoport S.I. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J. Lipid Res. 47 (2006) 172-180
94. Levant B., Radel J.D., and Carlson S.E. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behav. Brain Res. 152 (2004) 49-57
95. Nakashima Y., Yuasa S., Hukamizu Y., Okuyama H., Ohhara T., Kameyama T., and Nabeshima T. Effect of a high linoleate and a high alpha-linolenate diet on general behavior and drug sensitivity in mice. J. Lipid Res. 34 (1993) 239-247
96. McNamara R.K., Sullivan J., Richtand N.M., Campbell N., and Lipton J.W. Omega-3 fatty acid deficiency increases dopamine concentrations in the nucleus accumbens and augments amphetamine-induced sensitization in sensitization-resistant inbred DBA/2J mice. Biol. Psychiatry 59 (2006) S242
97. Anderson G.J., Neuringer M., Lin D.S., and Connor W.E. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr. Res. 58 (2005) 865-872
98. Sarkadi-Nagy E., Wijendran V., Diau G.Y., Chao A.C., Hsieh A.T., Turpeinen A., Nathanielsz P.W., and Brenna J.T. The influence of prematurity and long chain polyunsaturate supplementation in 4-week adjusted age baboon neonate brain and related tissues. Pediatr. Res. 54 (2003) 244-252
99. Sarkadi-Nagy E., Wijendran V., Diau G.Y., Chao A.C., Hsieh A.T., Turpeinen A., Lawrence P., Nathanielsz P.W., and Brenna J.T. Formula feeding potentiates docosahexaenoic and arachidonic acid biosynthesis in term and preterm baboon neonates. J. Lipid Res. 45 (2004) 71-80
100. Connor W.E., Neuringer M., and Lin D.S. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J. Lipid Res. 31 (1990) 237-247
101. Neuringer M., Connor W.E., Van Petten C., and Barstad L. Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys. J. Clin. Invest. 73 (1984) 272-276
102. Reisbick S., Neuringer M., Gohl E., Wald R., and Anderson G.J. Visual attention in infant monkeys: effects of dietary fatty acids and age. Dev. Psychol. 33 (1997) 387-395
103. Reisbick S., Neuringer M., Hasnain R., and Connor W.E. Polydipsia in rhesus monkeys deficient in omega-3 fatty acids. Physiol. Behav. 47 (1990) 315-323
104. Reisbick S., Neuringer M., Hasnain R., and Connor W.E. Home cage behavior of rhesus monkeys with long-term deficiency of omega-3 fatty acids. Physiol. Behav. 55 (1994) 231-239
105. Diau G.Y., Loew E.R., Wijendran V., Sarkadi-Nagy E., Nathanielsz P.W., and Brenna J.T. Docosahexaenoic and arachidonic acid influence on preterm baboon retinal composition and function. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4559-4566
106. Clandinin M.T., Chappell J.E., Leong S., Heim T., Swyer P.R., and Chance G.W. Intrauterine fatty acid accretion rates in human brain: implications for fatty acid requirements. Early Hum. Dev. 4 (1980) 121-129
107. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 120 (1992) S129-S138
108. Carver J.D., Benford V.J., Han B., and Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 56 (2001) 79-85
109. Giedd J.N., Blumenthal J., Jeffries N.O., Castellanos F.X., Liu H., Zijdenbos A., Paus T., Evans A.C., and Rapoport J.L. Brain development during childhood and adolescence: a longitudinal MRI study. Nat. Neurosci. 2 (1999) 861-863
110. Tisserand D.J., Pruessner J.C., Sanz Arigita E.J., van Boxtel M.P., Evans A.C., Jolles J., and Uylings H.B. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. Neuroimage 17 (2002) 657-669
111. Carlson S.E., Rhodes P.G., and Ferguson M.G. Docosahexaenoic acid status of preterm infants at birth and following feeding with human milk or formula. Am. J. Clin. Nutr. 44 (1986) 798-804
112. Carlson S.E., and Neuringer M. Polyunsaturated fatty acid status and neurodevelopment: a summary and critical analysis of the literature. Lipids 34 (1999) 171-178
113. Uauy R., Hoffman D.R., Peirano P., Birch D.G., and Birch E.E. Essential fatty acids in visual and brain development. Lipids 36 (2001) 885-895
114. Gibson R.A., Neumann M.A., and Makrides M. Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Lipids 31 (1996) S177-S181
115. Jamieson E.C., Farquharson J., Logan R.W., Howatson A.G., Patrick W.J., Weaver L.T., and Cockburn F. Infant cerebellar gray and white matter fatty acids in relation to age and diet. Lipids 34 (1999) 1065-1071
116. Nosarti C., Al-Asady M.H., Frangou S., Stewart A.L., Rifkin L., and Murray R.M. Adolescents who were born very preterm have decreased brain volumes. Brain 125 (2002) 1616-1623
117. Peterson B.S., Vohr B., Staib L.H., Cannistraci C.J., Dolberg A., Schneider K.C., Katz K.H., Westerveld M., Sparrow S., Anderson A.W., Duncan C.C., Makuch R.W., Gore J.C., and Ment L.R. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. J. Am. Med. Assoc. 284 (2000) 1939-1947
118. Stewart A.L., Rifkin L., Amess P.N., Kirkbride V., Townsend J.P., Miller D.H., Lewis S.W., Kingsley D.P., Moseley I.F., Foster O., and Murray R.M. Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm. Lancet 353 (1999) 1653-1657
119. Nagy Z., Westerberg H., Skare S., Andersson J.L., Lilja A., Flodmark O., Fernell E., Holmberg K., Bohm B., Forssberg H., Lagercrantz H., and Klingberg T. Preterm children have disturbances of white matter at 11 years of age as shown by diffusion tensor imaging. Pediatr. Res. 54 (2003) 672-679
120. Bhutta A.T., Cleves M.A., Casey P.H., Cradock M.M., and Anand K.J. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. J. Am. Med. Assoc. 288 (2002) 728-737
121. Botting N., Powls A., Cooke R.W., and Marlow N. Attention deficit hyperactivity disorders and other psychiatric outcomes in very low birthweight children at 12 years. J. Child Psychol. Psychiatry 38 (1997) 931-941
122. Cherkes-Julkowski M. Learning disability, attention-deficit disorder, and language impairment as outcomes of prematurity: a longitudinal descriptive study. J. Learn. Disabil. 31 (1998) 294-306
123. Cooke R.W., and Foulder-Hughes L. Growth impairment in the very preterm and cognitive and motor performance at 7 years. Arch. Dis. Child 88 (2003) 482-487
124. Foulder-Hughes L.A., and Cooke R.W. Motor, cognitive, and behavioural disorders in children born very preterm. Dev. Med. Child Neurol. 45 (2003) 97-103
125. Lawson K.R., and Ruff H.A. Early focused attention predicts outcome for children born prematurely. J. Dev. Behav. Pediatr. 25 (2004) 399-406
126. Olsen P., Vainionpaa L., Paakko E., Korkman M., Pyhtinen J., and Jarvelin M.R. Psychological findings in preterm children related to neurologic status and magnetic resonance imaging. Pediatrics 102 (1998) 329-336
127. Salt A., and Redshaw M. Neurodevelopmental follow-up after preterm birth: follow up after two years. Early Hum. Dev. 82 (2006) 185-197
128. Schothorst P.F., and van Engeland H. Long-term behavioral sequelae of prematurity. J. Am. Acad. Child Adolesc. Psychiatry 35 (1996) 175-183
129. Carlson S.E., and Werkman S.H. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until two months. Lipids 31 (1996) 85-90
130. Werkman S.H., and Carlson S.E. A randomized trial of visual attention of preterm infants fed docosahexaenoic acid until nine months. Lipids 31 (1996) 91-97
131. Helland I.B., Smith L., Saarem K., Saugstad O.D., and Drevon C.A. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics 111 (2003) 39-44
132. Cheruku S.R., Montgomery-Downs H.E., Farkas S.L., Thoman E.B., and Lammi-Keefe C.J. Higher maternal plasma docosahexaenoic acid during pregnancy is associated with more mature neonatal sleep-state patterning. Am. J. Clin. Nutr. 76 (2002) 608-613
133. Williams C., Birch E.E., Emmett P.M., and Northstone K. Stereoacuity at age 3.5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. Am. J. Clin. Nutr. 73 (2001) 316-322
134. Colombo J., Kannass K.N., Shaddy D.J., Kundurthi S., Maikranz J.M., Anderson C.J., Blaga O.M., and Carlson S.E. Maternal DHA and the development of attention in infancy and toddlerhood. Child Dev. 75 (2004) 1254-1267
135. P. Willatts, S. Forsyth, G. Mires, P. Ross, Maternal DHA status in late pregnancy is related to infant look duration and acuity at age 4 months. Poster presented at the meeting of the Society for Research in Child Development, Tampa, FL, 2003.
136. Innis S.M., Gilley J., and Werker J. Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants?. J. Pediatr. 139 (2001) 532-538
137. Daniels J.L., Longnecker M.P., Rowland A.S., Golding J., and the ALSPAC Study Team. Fish intake during pregnancy and early cognitive development of offspring. Epidemiology 15 (2004) 394-402
138. Oken E., Wright R.O., Kleinman K.P., Bellinger D., Hu H., Rich-Edwards J.W., and Gillman M.W. Maternal fish consumption, hair mercury, and infant cognition in a US cohort. Env. Health Persp. 113 (2005) 1376-1380
139. Innis S.M. Polyunsaturated fatty acids in human milk: an essential role in infant development. Adv. Exp. Med. Biol. 554 (2004) 27-43
140. Francois C.A., Connor S.L., Bolewicz L.C., and Connor W.E. Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am. J. Clin. Nutr. 77 (2003) 226-233
141. 〈www.DHAdoc.com/articles.html〉
142. Sanders T.A., and Naismith D.J. A comparison of the influence of breast-feeding and bottle-feeding on the fatty acid composition of the erythrocytes. Br. J. Nutr. 41 (1979) 619-623
143. Putnam J.C., Carlson S.E., DeVoe P.W., and Barness L.A. The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants. Am. J. Clin. Nutr. 36 (1982) 106-114
144. Auestad N., Montalto M.B., Hall R.T., Fitzgerald K.M., Wheeler R.E., Connor W.E., Neuringer M., Connor S.L., Taylor J.A., and Hartmann E.E. Visual acuity, erythrocyte fatty acid composition, and growth in term infants fed formulas with long chain polyunsaturated fatty acids for one year. Ross Pediatric Lipid Study. Pediatr. Res. 41 (1997) 1-10
145. H.M. Schachter, K. Kourad, Z. Merali, A. Lumb, K. Tran, M. Miguelez, et al., Effects of Omega-3 Fatty Acids on Mental Health. Summary, Evidence Report/Tecnology Assessment #116 (Prepared by the University of Ottawa Evidence-based Practice Center under Contract No. 290-02-0021). AHRQ Publication No. 05-E022-1. Agency for Healthcare Research and Quality, Rockville, MD, 2005.
146. Uauy R., Birch E., Birch D., and Peirano P. Visual and brain function measurements in studies of n-3 fatty acid requirements of infants. J. Pediatr. 120 (1992) S168-S180
147. Carlson S.E., Werkman S.H., Rhodes P.G., and Tolley E.A. Visual-acuity development in healthy preterm infants: effect of marine-oil supplementation. Am. J. Clin. Nutr. 58 (1993) 35-42
148. Agostoni C., Trojan S., Bellu R., Riva E., and Giovannini M. Neurodevelopmental quotient of healthy term infants at 4 months and feeding practice: the role of long-chain polyunsaturated fatty acids. Pediatr. Res. 38 (1995) 262-266
149. Khedr E.M., Farghaly W.M., Amry S.-D., and Osman A.A. Neural maturation of breastfed and formula-fed infants. Acta Paediatr. 93 (2004) 734-738
150. Jensen C.L., Voigt R.G., Prager T.C., Zou Y.L., Fraley J.K., Rozelle J.C., Turcich M.R., Llorente A.M., Anderson R.E., and Heird W.C. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am. J. Clin. Nutr. 82 (2005) 125-132
151. Clandinin M.T., Van Aerde J.E., Merkel K.L., Harris C.L., Springer M.A., Hansen J.W., and Diersen-Schade D.A. Growth and development of preterm infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J. Pediatr. 146 (2005) 461-468
152. Morale S.E., Hoffman D.R., Castaneda Y.S., Wheaton D.H., Burns R.A., and Birch E.E. Duration of long-chain polyunsaturated fatty acids availability in the diet and visual acuity. Early Hum. Dev. 81 (2005) 197-203
153. Lauritzen L., Hansen H.S., Jorgensen M.H., and Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 40 (2001) 1-94
154. Willatts P., Forsyth J.S., DiModugno M.K., Varma S., and Colvin M. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 352 (1998) 688-691
155. van Wezel-Meijler G., Van Der Knaap M.S., Huisman J., Jonkman E.J., Valk J., and Lafeber H.N. Dietary supplementation of long-chain polyunsaturated fatty acids in preterm infants: effects on cerebral maturation. Acta Paediatrica 91 (2002) 942-950
156. Holman R.T., Johnson S.B., and Hatch T.F. A case of human linolenic acid deficiency involving neurological abnormalities. Am. J. Clin. Nutr. 35 (1982) 617-623
157. Holman R.T. The slow discovery of the importance of omega 3 essential fatty acids in human health. J. Nutr. 128 (1998) 427S-433S
158. Biederman J., Monuteaux M.C., Mick E., Spencer T., Wilens T.E., Klein K.L., Price J.E., and Faraone S.V. Psychopathology in females with attention-deficit/hyperactivity disorder: a controlled, five-year prospective study. Biol. Psychiatry (2006) [Epub ahead of print]
159. Erlenmeyer-Kimling L., Rock D., Roberts S.A., Janal M., Kestenbaum C., Cornblatt B., Adamo U.H., and Gottesman I.I. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry 157 (2000) 1416-1422
160. Keshavan M.S., Sujata M., Mehra A., Montrose D.M., and Sweeney J.A. Psychosis proneness and ADHD in young relatives of schizophrenia patients. Schizophr. Res. 59 (2003) 85-92
161. Keshavan M.S., Diwadkar V.A., Montrose D.M., Rajarethinam R., and Sweeney J.A. Premorbid indicators and risk for schizophrenia: a selective review and update. Schizophr. Res. 79 (2005) 45-57
162. Mitchell E.A., Lewis S., and Cutler D.R. Essential fatty acids and maladjusted behaviour in children. Prostagland. Leukot. Med. 12 (1983) 281-287
163. Mitchell E.A. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin. Pediatr. 26 (1987) 406-411
164. Stevens L.J., Zentall S.S., Deck J.L., Abate M.L., Watkins B.A., Lipp S.R., and Burgess J.R. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 62 (1995) 761-768
165. Chen J.R., Hsu S.F., Hsu C.D., Hwang L.H., and Yang S.C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J. Nutr. Biochem. 15 (2004) 467-472
166. Young G.S., Maharaj N.J., and Conquer J.A. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 39 (2004) 117-123
167. Richardson A.J., and Puri B.K. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog. Neuropsychopharm Biol. Psychiatry 26 (2002) 233-239
168. Hirayama S., Hamazaki T., and Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder-a placebo-controlled double-blind study. Eur. J. Clin. Nutr. 58 (2004) 467-473
169. Brue A.W., Oakland T.D., and Evans R.A. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci. Rev. Alt. Med. 5 (2001) 187-194
170. Harding K.L., Judah R.D., and Gant C.E. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. Alt. Med. Rev. 8 (2003) 319-330
171. Voigt R.G., Llorente A.M., Jensen C.L., Fraley J.K., Berretta M.C., and Heird W.C. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J. Pediatr. 139 (2001) 189-196
172. Stevens L., Zhang W., Peck L., Kuczek T., Grevstad N., Mahon A., Zentall S.S., Arnold L.E., and Burgess J.R. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38 (2003) 1007-1021
173. Joshi K., Lad S., Kale M., Patwardhan B., Mahadik S.P., Patni B., Chaudhary A., Bhave S., and Pandit A. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot. Essent. Fatty Acids 74 (2006) 17-21
174. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., and Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J. Neurosci. 18 (1998) 5901-5907
175. Rosa Neto P., Lou H., Cumming P., Pryds O., and Gjedde A. Methylphenidate-evoked potentiation of extracellular dopamine in the brain of adolescents with premature birth: correlation with attentional deficit. Ann. NY Acad. Sci. 965 (2002) 434-439
176. Swanson C.J., Perry K.W., Koch-Krueger S., Katner J., Svensson K.A., and Bymaster F.P. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50 (2006) 755-760
177. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
178. Kalsbeek A., Voorn P., Buijs R.M., Pool C.W., and Uylings H.B. Development of the dopaminergic innervation in the prefrontal cortex of the rat. J. Comp. Neurol. 269 (1988) 58-72
179. Ilgin N., Senol S., Gucuyener K., Gokcora N., and Sener S. Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev. Med. Child Neurol. 43 (2001) 755-760
180. Volkow N.D., Wang G.J., Fowler J.S., and Ding Y.S. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1410-1415
181. Verney C., Milosevic A., Alvarez C., and Berger B. Immunocytochemical evidence of well-developed dopaminergic and noradrenergic innervations in the frontal cerebral cortex of human fetuses at midgestation. J. Comp. Neurol. 336 (1993) 331-344
182. Zecevic N., and Verney C. Development of the catecholamine neurons in human embryos and fetuses, with special emphasis on the innervation of the cerebral cortex. J. Comp. Neurol. 351 (1995) 509-535
183. Kadziela-Olech H., and Piotrowska-Jastrzebska J. The duration of breastfeeding and attention deficit hyperactivity disorder. Rocz. Akad. Med. Bialymst. 50 (2005) 302-306
184. Castellanos F.X., Lee P.P., Sharp W., Jeffries N.O., Greenstein D.K., Clasen L.S., Blumenthal J.D., James R.S., Ebens C.L., Walter J.M., Zijdenbos A., Evans A.C., Giedd J.N., and Rapoport J.L. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Med. Assoc. 288 (2002) 1740-1748
185. Sowell E.R., Thompson P.M., Welcome S.E., Henkenius A.L., Toga A.W., and Peterson B.S. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 362 (2003) 1699-1707
186. Hill D.E., Yeo R.A., Campbell R.A., Hart B., Vigil J., and Brooks W. Magnetic resonance imaging correlates of attention-deficit/hyperactivity disorder in children. Neuropsychology 17 (2003) 496-506
187. Lyoo I.K., Noam G.G., Lee C.K., Lee H.K., Kennedy B.P., and Renshaw P.F. The corpus callosum and lateral ventricles in children with attention-deficit hyperactivity disorder: a brain magnetic resonance imaging study. Biol. Psychiatry 40 (1996) 1060-1063
188. Seidman L.J., Valera E.M., and Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1263-1272
189. Christensen O., and Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 78 (1988) 587-591
190. Stokes C., and Peet M. Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr. Neurosci. 7 (2004) 247-249
191. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., and Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 393-399
192. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., and Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58 (2002) 1-10
193. Reddy R.D., Keshavan M.S., and Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 30 (2004) 901-911
194. Assies J., Lieverse R., Vreken P., Wanders R.J., Dingemans P.M., and Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry 49 (2001) 510-522
195. Peet M., Laugharne J., Rangarajan N., Horrobin D., and Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29 (1995) 227-232
196. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., and Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121 (2003) 109-122
197. McNamara R.K., Hahn C.-G., Richtand N.M., Jandacek R.J., and Tso P. Reductions in the principle brain omega-3 fatty acid, docosahexaenoic acid, in postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder, but not multiple sclerosis or Alzheimer's disease. Biol. Psychiatry 59 (2006) S30
198. McNamara R.K., Hahn C.-G., Richtand N.M., Jandacek R.J., and Tso P. Fatty acid composition of the prefrontal and temporal cortex of schizophrenic, bipolar, and depressed patients. Biol. Psychiatry 57 (2005) S192
199. Landen M., Davidsson P., Gottfries C.G., Mansson J.E., and Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr. Res. 55 (2002) 83-88
200. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17
201. Horrobin D.F., Manku M.S., Hillman H., Iain A., and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30 (1991) 795-805
202. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., and Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr. Res. 62 (2003) 195-204
203. Emsley R., Myburgh C., Oosthuizen P., and van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 159 (2002) 1596-1598
204. Mellor J.E., Laugharne J.D., and Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophr. Res. 18 (1995) 85-86
205. Peet M., Brind J., Ramchand C.N., Shah S., and Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 49 (2001) 243-251
206. Peet M., Horrobin D.F., and E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 36 (2002) 7-18
207. Dalman C., Allebeck P., Cullberg J., Grunewald C., and Koster M. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch. Gen. Psychiatry 56 (1999) 234-240
208. Ichiki M., Kunugi H., Takei N., Murray R.M., Baba H., Arai H., Oshima I., Okagami K., Sato T., Hirose T., and Nanko S. Intra-uterine physical growth in schizophrenia: evidence confirming excess of premature birth. Psychol. Med. 30 (2000) 597-604
209. Geddes J.R., Verdoux H., Takei N., Lawrie S.M., Bovet P., Eagles J.M., Heun R., McCreadie R.G., McNeil T.F., O'Callaghan E., Stober G., Willinger U., and Murray R.M. Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis. Schizophr. Bull. 25 (1999) 413-423
210. Jones P.B., Rantakallio P., Hartikainen A.L., Isohanni M., and Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am. J. Psychiatry 155 (1998) 355-364
211. Smith G.N., Flynn S.W., McCarthy N., Meistrich B., Ehmann T.S., MacEwan G.W., Altman S., Kopala L.C., and Honer W.G. Low birthweight in schizophrenia: prematurity or poor fetal growth?. Schizophr. Res. 47 (2001) 177-184
212. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
213. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J. Neural Transm. Suppl. 36 (1992) 61-89
214. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44 (1987) 660-669
215. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
216. Westerink B.H., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., and Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412 (2001) 127-138
217. Gray J.A., and Roth B.L. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res. Bull. 56 (2001) 441-451
218. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 297 (2001) 711-717
219. Amore M., Balista C., McCreadie R.G., Cimmino C., Pisani F., Bevilacqua G., and Ferrari G. Can breast-feeding protect against schizophrenia? Case-control study. Biol. Neonate 83 (2003) 97-101
220. McCreadie R.G. The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: preliminary results and hypotheses,. Br. J. Psychiatry 170 (1997) 334-337
221. Sorensen H.J., Mortensen E.L., Reinisch J.M., and Mednick S.A. Breastfeeding and risk of schizophrenia in the Copenhagen Perinatal Cohort. Acta Psychiatr. Scand. 112 (2005) 26-29
222. Leask S.J., Done D.J., Crow T.J., Richards M., and Jones P.B. No association between breast-feeding and adult psychosis in two national birth cohorts. Br. J. Psychiatry 177 (2000) 218-221
223. Sasaki T., Okazaki Y., Akaho R., Masui K., Harada S., Lee I., Takazawa S., Takahashi S., Iida S., and Takakuwa M. Type of feeding during infancy and later development of schizophrenia. Schizophr. Res. 42 (2000) 79-82
224. Keller A., Jeffries N.O., Blumenthal J., Clasen L.S., Liu H., Giedd J.N., and Rapoport J.L. Corpus callosum development in childhood-onset schizophrenia. Schizophr. Res. 62 (2003) 105-114
225. Mehler C., and Warnke A. Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. J. Neural. Transm. 109 (2002) 219-234
226. Rapoport J.L., Giedd J.N., Blumenthal J., Hamburger S., Jeffries N., Fernandez T., Nicolson R., Bedwell J., Lenane M., Zijdenbos A., Paus T., and Evans A. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 56 (1999) 649-654
227. Sowell E.R., Toga A.W., and Asarnow R. Brain abnormalities observed in childhood-onset schizophrenia: a review of the structural magnetic resonance imaging literature. Ment. Retard. Dev. Disabil. Res. Rev. 6 (2000) 180-185
228. Thompson P.M., Vidal C., Giedd J.N., Gochman P., Blumenthal J., Nicolson R., Toga A.W., and Rapoport J.L. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. USA 98 (2001) 11650-11655
229. Bachmann S., Pantel J., Flender A., Bottmer C., Essig M., and Schroder J. Corpus callosum in first-episode patients with schizophrenia-a magnetic resonance imaging study. Psychol. Med. 33 (2003) 1019-1027
230. Bogerts B., Ashtari M., Degreef G., Alvir J.M., Bilder R.M., and Lieberman J.A. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 35 (1990) 1-13
231. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., Smith G.N., Arango V., Mann J.J., Dwork A.J., Falkai P., and Honer W.G. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry 8 (2003) 811-820
232. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., and Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 155 (1998) 1711-1717
233. Gur R.E., Cowell P.E., Latshaw A., Turetsky B.I., Grossman R.I., Arnold S.E., Bilker W.B., and Gur R.C. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 761-768
234. Keshavan M.S., Diwadkar V.A., Harenski K., Rosenberg D.R., Sweeney J.A., and Pettegrew J.W. Abnormalities of the corpus callosum in first episode, treatment naive schizophrenia. J. Neurol. Neurosurg. Psychiatry 72 (2002) 757-760
235. Lim K.O., Tew W., Kushner M., Chow K., Matsumoto B., and DeLisi L.E. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am. J. Psychiatry 153 (1996) 1548-1553
236. Nopoulos P., Torres I., Flaum M., Andreasen N.C., Ehrhardt J.C., and Yuh W.T. Brain morphology in first-episode schizophrenia. Am. J. Psychiatry 152 (1995) 1721-1723
237. Szeszko P.R., Goldberg E., Gunduz-Bruce H., Ashtari M., Robinson D., Malhotra A.K., Lencz T., Bates J., Crandall D.T., Kane J.M., and Bilder R.M. Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am. J. Psychiatry 160 (2003) 2190-2197
238. Velakoulis D., Pantelis C., McGorry P.D., Dudgeon P., Brewer W., Cook M., Desmond P., Bridle N., Tierney P., Murrie V., Singh B., and Copolov D. Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Arch. Gen. Psychiatry 56 (1999) 133-141
239. Honea R., Crow T.J., Passingham D., and Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162 (2005) 2233-2245
240. Arnold S.E., Franz B.R., Gur R.C., Gur R.E., Shapiro R.M., Moberg P.J., and Trojanowski J.Q. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am. J. Psychiatry 152 (1995) 738-748
241. Benes F.M., Sorensen I., and Bird E.D. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr. Bull. 17 (1991) 597-608
242. Broadbelt K., Byne W., and Jones L.B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr. Res. 58 (2002) 75-81
243. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., and Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry 65 (1998) 446-453
244. Glantz L.A., and Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 65-73
245. Karson C.N., Mrak R.E., Schluterman K.O., Sturner W.Q., Sheng J.G., and Griffin W.S. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol. Psychiatry 4 (1999) 39-45
246. Rosoklija G., Toomayan G., Ellis S.P., Keilp J., Mann J.J., Latov N., Hays A.P., and Dwork A.J. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch. Gen. Psychiatry 57 (2000) 349-356
247. Baare W.F., van Oel C.J., Hulshoff Pol H.E., Schnack H.G., Durston S., Sitskoorn M.M., and Kahn R.S. Volumes of brain structures in twins discordant for schizophrenia. Arch. Gen. Psychiatry 58 (2001) 33-40
248. Cannon T.D., Thompson P.M., van Erp T.G., Toga A.W., Poutanen V.P., Huttunen M., Lonnqvist J., Standerskjold-Nordenstam C.G., Narr K.L., Khaledy M., Zoumalan C.I., Dail R., and Kaprio J. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc. Natl. Acad. Sci. USA 99 (2002) 3228-3233
249. McNeil T.F., Cantor-Graae E., and Weinberger D.R. Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia. Am. J. Psychiatry 157 (2000) 203-212
250. Suddath R.L., Christison G.W., Torrey E.F., Casanova M.F., and Weinberger D.R. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N. Engl. J. Med. 322 (1990) 789-794
251. Kunugi H., Urushibara T., Murray R.M., Nanko S., and Hirose T. Prenatal underdevelopment and schizophrenia: a case report of monozygotic twins. Psychiatry Clin. Neurosci. 57 (2003) 271-274
252. Hoving E.B., van Beusekom C.M., Nijeboer H.J., and Muskiet F.A. Gestational age dependency of essential fatty acids in cord plasma cholesterol esters and triglycerides. Pediatr. Res. 35 (1994) 461-469
253. Bates C., Horrobin D.F., and Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr. Res. 6 (1991) 1-7
254. Gilbert A.R., Montrose D.M., Sahni S.D., Diwadkar V.A., and Keshavan M.S. Obstetric complications correlate with neurobehavioral and brain structural alterations in young relatives at risk for schizophrenia. Ann NY Acad. Sci. 1008 (2003) 269-275
255. Keshavan M.S., Dick E., Mankowski I., Harenski K., Montrose D.M., Diwadkar V., and DeBellis M. Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia. Schizophr. Res. 58 (2002) 173-183
256. Lawrie S.M., Whalley H., Kestelman J.N., Abukmeil S.S., Byrne M., Hodges A., Rimmington J.E., Best J.J., Owens D.G., and Johnstone E.C. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 353 (1999) 30-33
257. Lawrie S.M., Whalley H.C., Abukmeil S.S., Kestelman J.N., Donnelly L., Miller P., Best J.J., Owens D.G., and Johnstone E.C. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol. Psychiatry 49 (2001) 811-823
258. Cornblatt B.A. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am. J. Med. Genet. 114 (2002) 956-966
259. Oner O., and Munir K. Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. Schizophr. Res. 76 (2005) 293-299
260. Francois C.A., Connor S.L., Wander R.C., and Connor W.E. Acute effects of dietary fatty acids on the fatty acids of human milk. Am. J. Clin. Nutr. 67 (1998) 301-308
261. Lauritzen L., Jorgensen M.H., Hansen H.S., and Michaelsen K.F. Fluctuations in human milk long-chain PUFA levels in relation to dietary fish intake. Lipids 37 (2002) 237-244
262. Makrides M., Neumann M.A., and Gibson R.A. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur. J. Clin. Nutr. 50 (1996) 352-357
263. Marangoni F., Agostoni C., Lammardo A.M., Bonvissuto M., Giovannini M., Galli C., and Riva E. Polyunsaturated fatty acids in maternal plasma and in breast milk. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 535-540
264. Haggarty P., Page K., Abramovich D.R., Ashton J., and Brown D. Long-chain polyunsaturated fatty acid transport across the perfused human placenta. Placenta 18 (1997) 635-642
265. Haggarty P., Ashton J., Joynson M., Abramovich D.R., and Page K. Effect of maternal polyunsaturated fatty acid concentration on transport by the human placenta. Biol. Neonate 75 (1999) 350-359
266. Haggarty P., Abramovich D.R., and Page K. The effect of maternal smoking and ethanol on fatty acid transport by the human placenta. Br. J. Nutr. 87 (2002) 247-252
267. Dutta-Roy A.K. Transport mechanisms for long-chain polyunsaturated fatty acids in the human placenta. Am. J. Clin. Nutr. 71 (2000) S315-S322
268. Jensen R.G., Bitman J., Carlson S.E., Couch S.C., Hamosh M., and Newburg D.S. Milk lipids. A. Human milk lipids. In: Jensen R.E. (Ed). Handbook of Milk Composition (1995), Academic Press, Inc., New York 495-542
269. Hibbeln J.R., Makino K.K., Martin C.E., Dickerson F., Boronow J., and Fenton W.S. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry 53 (2003) 431-441
270. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., and Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry 152 (1995) 453-455
271. Nilsson E., Lichtenstein P., Cnattingius S., Murray R.M., and Hultman C.M. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr. Res. 58 (2002) 221-229
272. Araya J., Rojas M., Fernandez P., and Mateluna A. Essential fatty acid content of maternal erythrocyte phospholipids. A study in preterm and full-term human newborns. Rev. Med. Chil. 126 (1998) 391-396
273. Beijers R.J., and Schaafsma A. Long-chain polyunsaturated fatty acid content in Dutch preterm breast milk; differences in the concentrations of docosahexaenoic acid and arachidonic acid due to length of gestation. Early Hum. Dev. 44 (1996) 215-223
274. Helland I.B., Saugstad O.D., Smith L., Saarem K., Solvoll K., Ganes T., and Drevon C.A. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 108 (2001) E82
275. Olsen S.F., and Secher N.J. Low consumption of seafood in early pregnancy as a risk factor for preterm delivery: prospective cohort study. Br. Med. J. 324 (2002) 447
276. Olsen S.F., Sorensen J.D., Secher N.J., Hedegaard M., Henriksen T.B., Hansen H.S., and Grant A. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 339 (1992) 1003-1007
277. Smuts C.M., Huang M., Mundy D., Plasse T., Major S., and Carlson S.E. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet. Gynecol. 101 (2003) 469-479
278. Bennedsen B.E., Mortensen P.B., Olesen A.V., and Henriksen T.B. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br. J. Psychiatry 175 (1999) 239-245
279. Ichiki M., Kunugi H., Takei N., Murray R.M., Baba H., Arai H., Oshima I., Okagami K., Sato T., Hirose T., and Nanko S. Intra-uterine physical growth in schizophrenia: evidence confirming excess of premature birth. Psychol. Med. 30 (2000) 597-604
280. Olsen S.F., Secher N.J., Tabor A., Weber T., Walker J.J., and Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 107 (2000) 382-395
281. Dunstan J.A., Mori T.A., Barden A., Beilin L.J., Holt P.G., Calder P.C., Taylor A.L., and Prescott S.L. Effects of n-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. Eur. J. Clin. Nutr. 58 (2004) 429-437
282. Connor W.E., Lowensohn R., and Hatcher L. Increased docosahexaenoic acid levels in human newborn infants by administration of sardines and fish oil during pregnancy. Lipids 31 (1996) S183-S187
283. Montgomery C., Speake B.K., Cameron A., Sattar N., and Weaver L.T. Maternal docosahexaenoic acid supplementation and fetal accretion. Br. J. Nutr. 90 (2003) 135-145
284. van Houwelingen A.C., Sorensen J.D., Hornstra G., Simonis M.M., Boris J., Olsen S.F., and Secher N.J. Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy. Br. J. Nutr. 74 (1995) 723-731
285. Boris J., Jensen B., Salvig J.D., Secher N.J., and Olsen S.F. A randomized controlled trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 fatty acid content in human breast milk. Lipids 39 (2004) 1191-1196
286. Lauritzen L., Jorgensen M.H., Mikkelsen T.B., Skovgaard M., Straarup E.M., Olsen S.F., Hoy C.E., and Michaelsen K.F. Maternal fish oil supplementation in lactation: effect on visual acuity and n-3 fatty acid content of infant erythrocytes. Lipids 39 (2004) 195-206
287. Velzing-Aarts F.V., van der Klis F.R., van der Dijs F.P., van Beusekom C.M., Landman H., Capello J.J., and Muskiet F.A. Effect of three low-dose fish oil supplements, administered during pregnancy, on neonatal long-chain polyunsaturated fatty acid status at birth. Prostaglandins Leukot. Essent. Fatty Acids 65 (2001) 51-57
288. Williams M.A., Zingheim R.W., King I.B., and Zebelman A.M. Omega-3 fatty acids in maternal erythrocytes and risk of preeclampsia. Epidemiology 6 (1995) 232-237
289. Ward R.K., and Zamorski M.A. Benefits and risks of psychiatric medications during pregnancy. Am. Fam. Physician 66 (2002) 629-636
290. Su K.P., Shen W.W., and Huang S.Y. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Eur. Neuropsychopharmacol. 11 (2001) 295-299
291. Kitessa S.M., Gulati S.K., Simos G.C., Ashes J.R., Scott T.W., Fleck E., and Wynn P.C. Supplementation of grazing dairy cows with rumen-protected tuna oil enriches milk fat with n-3 fatty acids without affecting milk production or sensory characteristics. Br. J. Nutr. 91 (2004) 271-278
292. Kris-Etherton P.M., Taylor D.S., Yu-Poth S., Huth P., Moriarty K., Fishell V., Hargrove R.L., Zhao G., and Etherton T.D. Polyunsaturated fatty acids in the food chain in the United States. Am. J. Clin. Nutr. 71 (2000) S179-S188
293. Raper N.R., Cronin F.J., and Exler J. Omega-3 fatty acid content of the US food supply. J. Am. Coll. Nutr. 11 (1992) 304-308
294. Simopoulos A.P. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 70 (1999) S560-S569
295. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 56 (2002) 365-379
296. Oken E., Kleinman K.P., Berland W.E., Simon S.R., Rich-Edwards J.W., and Gillman M.W. Decline in fish consumption among pregnant women after a national mercury advisory. Obstet. Gynecol. 102 (2003) 346-351
297. IOM Committee on Nutrient Relationships in Seafood: Selections to Balance Benefits and Risks, 2006, to be published.